The Hygiology Post is presenting information about a company that seems to have much potential to help many people. 2012 may be a pivotal year in determining how helpful the patented technologies may actually be for people.
Senesco Technologies has continued to update information on its web site (https://www.senesco.com/; obtained on 11-07-12). As a matter of disclosure : The author continues to be a current shareholder in the company.
The Senesco Technologies web site ( https://www.senesco.com/newsitem.php?id=263; obtained on 11-7-12) has posted relevant information about its its research. Here is an excerpt:
Senesco Announces Expansion of Phase 1b/2a Study to Include Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma First DLBCL Patient Dosed in Study
BRIDGEWATER, N.J. (November 7th, 2012) – Senesco Technologies, Inc. (‘Senesco’ or the ‘Company’) (NYSE MKT: SNT) reported today that the clinical trial of SNS01-T has been expanded to include diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). The first patient with DLBCL was enrolled in cohort 2 and received the first dose last week.
‘We are very pleased to have expanded the study to include DLBCL and MCL, which like multiple myeloma, are B-cell cancers that SNS01-T was designed to treat. We submitted a protocol amendment to the FDA in August in order to open the study to patients suffering from these non-Hodgkin’s B-cell lymphomas,’ stated Leslie J. Browne, Ph.D., President and CEO of Senesco. ‘The ability to include other hematological cancers broadens our results and may accelerate patient enrollment at the three clinical sites where SNS01-T is being investigated. This should keep us on track to disclose results of cohort 2 around the end of 2012.’
Senesco previously reported that two of three patients, who completed dosing with SNS01-T in cohort 1 had not progressed on treatment, based on criteria including the monoclonal protein, and were considered stable at week 3 and week 6, the end of the dosing regimen.”
The Hygiology Post welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2012 The Hygiology Post